Skip to main content

Publications: Mrs Charlotte Ackerman

Szabados B, Duncan S, Choy J, Jackson-Spence F, Toms C, Trevisan G, Berney DM, Powles T et al. ( 2022 ) . Androgen Receptor Expression Is a Predictor of Poor Outcome in Urothelial Carcinoma . Frontiers in Urology vol. 2 ,
Tan WS, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P, Phull J, Hunter-Campbell P et al. ( 2022 ) . Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial . European Urology
Schmid P, Gomez-Pardo P, Wheatley D, Roy P, Krabisch P, Thill M, Ledwidge S, Thompson A et al. ( 2021 ) . 208P ARB: Phase II window of opportunity study of preoperative treatment with enzalutamide in ER+ve and TNBC . Annals of Oncology vol. 32 , s449 - s450 .
Jackson-Spence FE, Ackerman C, Khan M, Grant M, Soosaipillai G, Nally E, Choy J, Powles TB et al. ( 2021 ) . P0461 The role of angiogenic signatures in advanced urothelial carcinoma (aUC) treated with VEGF-targeted therapy . European Urology vol. 79 ,
Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S et al. ( 2020 ) . Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy . European Urology Focus vol. 6 , ( 5 ) 999 - 1005 .
Powles T, Gómez de Liaño A, Ackerman C ( 2017 ) . Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48–55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed: Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late? . European Urology vol. 72 , ( 5 ) e137 - e138 .
Schmid P, Blackhall F, Muthukumar D, Lester J, Khan S, Adams J, Illsley M, Macgregor C et al. ( 2017 ) . LBA53 A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers . Annals of Oncology vol. 28 ,
Shepherd STC, Hall P, Brown JE, Larkin JMG, Jones RJ, Ralph C, Hawkins RE, Chowdhury S et al. ( 2017 ) . Can dynamic changes in prognostic markers predict survival in patients receiving VEGF-targeted therapy in clear cell renal cell carcinoma? . Journal of Clinical Oncology . vol. 35 , e16061 - e16061 .
Ackerman C, Mariathasan S, Nickles D, Gomez De Liano Lista A, Wimalasingham AG, Szabados B, Powles T ( 2017 ) . Molecular subtyping of metastatic urothelial bladder cancer . Journal of Clinical Oncology . vol. 35 , 326 - 326 .
Powles T, Huddart RA, Elliott T, Sarker S-J, Ackerman C, Jones R, Hussain S, Crabb S et al. ( 2017 ) . Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer . J Clin Oncol vol. 35 , ( 1 ) 48 - 55 .
Powles THOMAS, Huddart RA, Elliott T, SARKER S-J, Ackerman CHARLOTTE, Jones R, Hussaine S, Crabb S et al. ( 2016 ) . A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients . Journal of Clinical Oncology
Powles T, Sarwar N, Stockdale A, Sarker S-J, Boleti E, Protheroe A, Jones R, Chowdhury S et al. ( 2016 ) . Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer . JAMA Oncology vol. 2 , ( 10 ) 1303 - 1309 .
Powles T, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E et al. ( 2016 ) . A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK) . Annals of Oncology vol. 27 , ( 5 ) 880 - 886 .
Powles T, Hussain SA, Protheroe A, Birtle A, Chakraborti PR, Huddart R, Jagdev S, Bahl A et al. ( 2016 ) . PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours . Journal of Clinical Oncology . vol. 34 , 430 - 430 .
Powles T, Kayani I, Blank CU, Chowdhury S, Horenblas S, Sarwar N, Nathan PD, Boleti E et al. ( 2010 ) . The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer . Journal of Clinical Oncology vol. 28 , ( 15_suppl ) 4603 - 4603 .